Press releases

• July 30, 2020 - Other press releaseEisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020
• July 22, 2020 - Other press releaseBioArctic’s partner Eisai to present update on the development of BAN2401 at Alzheimer’s Association International Conference 2020
• July 14, 2020 - Other press releaseNew global Phase 3 program of BAN2401 initiated in preclinical (asymptomatic) Alzheimer’s disease

Archive

Calendar

• October 14, 2020 08:00 CETInterim report January – September 2020
• February 4, 2021 08:00 CETFull Year Report January – December 2020

Interim report Q2 2020

BioArctic published the company’s Interim Report for the period January – June 2020 on Friday, July 10, 2020 at 08:00 a.m. CEST.

• Report
• Presentation
• Press release
• Webcast

Read more

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more